Skip to content

Embecta Corp. EMBC Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$0+100%
ICU Medical logo
ICU MedicalICUI
-$136K+92.0%

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s gain/loss on asset sales?
Embecta Corp. (EMBC) reported gain/loss on asset sales of $0 in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.